Status:
COMPLETED
Degludec Insulin Use in Critically Ill Patients
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Conditions:
Diabetes Mellitus
Critical Illness
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: Dysglycemia in critically ill patients is common, where 40% to 54% of patients were found to be hyperglycemic on intensive care unit admission. Several randomized controlled trials (RCT) ...
Eligibility Criteria
Inclusion
- Patients aged 18 years and above
- Newly admitted critically ill patients with diabetes and expected ICU stay ≥ 48 hours
- Medical or surgical ICU patients
Exclusion
- Patients who were already started on insulin infusion based on physician discretion.
- Postoperative patients with expected ICU stay less than 48 hours
- Diabetic ketoacidosis or hyperosmolar hyperglycemic state.
- Patients with Do-Not-Attempt-Resuscitation (DNAR) status or imminent plan to palliation due to terminal disease.
- Refusal of the treating physician to enroll the patient into the study.
- Patients with diabetes mellitus Type 1.
- Patients who already eating prior to study enrollment
Key Trial Info
Start Date :
May 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2024
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT06056167
Start Date
May 17 2023
End Date
May 30 2024
Last Update
June 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia